RTOG 1016: Phase III Trial of Radiotherapy Plus Cetuximab versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer
Aims: The purpose of this study is to compare the effects, good and/or bad, of two standard treatments for head and neck cancer: radiation therapy plus the drug cisplatin or radiation therapy plus the drug cetuximab. The two treatments may be comparable in treating head and neck cancer, but radiation and cetuximab may result in less severe side effects. This study is being done in patients whose head and neck cancer was caused by Human Papillomavirus Virus (HPV). Some studies have found that patients with HPV-positive oropharynx cancer have a better response to treatment and live longer. Thus, this study aims to see if treatment with radiation plus cetuximab has less side effects and is as effective as radiation plus cisplatin.
Diagnosis: HPV-Associated Oropharynx Cancer
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH12-288
Sponsor: Radiation Therapy Oncology Group
Contact: Interested patients should contact study coordinator Sabina Omercajic, CCRP at 847.570.1066
Open to Enrollment: Yes

HCN Tissue Bank: Tissue/Body Fluid Procurement and Clinical Data Collection for Patients with Malignancies of the Head and Neck Area and/or Pre-Malignant Changes
Aims: The purpose of this study is to collect tissue, blood, saliva, and/or clinical data (information about your treatment) from patients wtih a cancer in the head and neck area (or pre-malignant lesions) for research purposes. Certain genetic and biochemical changes are believed to lead to the development of head and neck cancer. Scientists are attempting to discover and understand the function of these changes. In the future, improved understanding of these changes may help us to better detect head and neck cancers and offer improved treatments.
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH13-276
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact study coordinator Sabina Omercajic, CCRP at 847.570.1066
Open to Enrollment: Yes

UC09-266-B: Randomied Double-Blind Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and aneck (SCCHN)
Aims: This research is being done, because even after surgery and radiation therapy most people with SCCHN have their cancer come back within 5 years. The safety of this drug will also be studied, as well as the drug's effect on different cells in the body.
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH14-190
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact study coordinator Sabina Omercajic, CCRP at 847.570.1066
Open to Enrollment: Yes

× Alternate Text